BillionToOne, Inc. Class A Common Stock

Price Chart

Risk-Adjusted Performance

BillionToOne, Inc. Class A Common Stock (BLLN) Price Performance

BillionToOne, Inc. Class A Common Stock (BLLN) trades on United States in USD. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at $74.08, down 2.53% from the previous close.

Over the past year, BLLN has traded between a low of $67.36 and a high of $130.18. The stock has lost 32.0% over this period. It is currently 43.1% below its 52-week high.

BillionToOne, Inc. Class A Common Stock has a market capitalization of $3.17B, with a price-to-earnings ratio of 493.64.

About BillionToOne, Inc. Class A Common Stock

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.